Dermatologic Toxicities Associated with Chronic Gamma-Secretase Inhibitor Treatment for Desmoid Tumor

    Therese Woodring, Geraldine O’Sullivan-Coyne, A. Chen, H.H. Kong
    Studysummary This study reports that 71% of patients treated with the gamma-secretase inhibitor PF-03084014 for desmoid tumors experienced dermatologic side effects, such as follicular lesions and pruritic eruptions, which were managed with topical or systemic treatments.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jidonline.org →
    Discuss this study in the Community →